XML 20 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional paid-in capital
Accumulated Other Comprehensive (Loss) Income
Accumulated deficit
Series A convertible preferred stock
Series B convertible preferred stock
Series C convertible preferred stock
Balances at Dec. 31, 2020 $ (117,441)   $ 14,598 $ (124) $ (131,915)      
Balance at Beginning of period at Dec. 31, 2020           $ 30,000 $ 68,995 $ 87,038
Balance at Beginning of period (in shares) at Dec. 31, 2020           2,857,142 2,600,645 7,500,665
Balance at Beginning of period (in shares) at Dec. 31, 2020   337,508            
Conversion of preferred stock to common stock upon closing of the initial public offering 186,033 $ 2 186,031          
Temporary equity, conversion of convertible preferred stock into common stock upon closing of the initial public offering (in shares)           (2,857,142) (2,600,645) (7,500,665)
Temporary equity, conversion of convertible preferred stock into common stock upon closing of the initial public offering           $ (30,000) $ (68,995) $ (87,038)
Conversion of preferred stock to common stock upon closing of the initial public offering (in shares)   16,079,230            
Sale of common stock in initial public offering, net of issuance costs 133,023 $ 1 133,022          
Sale of common stock in initial public offering, net of issuance costs (in shares)   8,625,000            
Stock-based compensation expense 1,832   1,832          
Unrealized gain on available-for-sale securities (43)     (43)        
Foreign exchange translation adjustment (65)     (65)        
Net loss (13,337)       (13,337)      
Balances at Mar. 31, 2021 190,002 $ 3 335,483 (232) (145,252)      
Balance at end of period (in shares) at Mar. 31, 2021   25,041,738            
Balances at Dec. 31, 2020 (117,441)   14,598 (124) (131,915)      
Balance at Beginning of period at Dec. 31, 2020           $ 30,000 $ 68,995 $ 87,038
Balance at Beginning of period (in shares) at Dec. 31, 2020           2,857,142 2,600,645 7,500,665
Balance at Beginning of period (in shares) at Dec. 31, 2020   337,508            
Foreign exchange translation adjustment (38)              
Balances at Sep. 30, 2021 172,156 $ 3 340,145 (167) (167,825)      
Balance at end of period (in shares) at Sep. 30, 2021   25,264,845            
Balances at Mar. 31, 2021 190,002 $ 3 335,483 (232) (145,252)      
Balance at Beginning of period (in shares) at Mar. 31, 2021   25,041,738            
Exercise of stock options 101   101          
Exercise of stock options (in shares)   17,446            
Vesting of restricted stock (in shares)   71,429            
Stock-based compensation expense 1,909   1,909          
Unrealized gain on available-for-sale securities 36     36        
Foreign exchange translation adjustment 22     22        
Net loss (10,738)       (10,738)      
Balances at Jun. 30, 2021 181,332 $ 3 337,493 (174) (155,990)      
Balance at end of period (in shares) at Jun. 30, 2021   25,130,613            
Exercise of stock options 797   797          
Exercise of stock options (in shares)   134,232            
Stock-based compensation expense 1,855   1,855          
Unrealized gain on available-for-sale securities 2     2        
Foreign exchange translation adjustment 5     5        
Net loss (11,835)       (11,835)      
Balances at Sep. 30, 2021 172,156 $ 3 340,145 (167) (167,825)      
Balance at end of period (in shares) at Sep. 30, 2021   25,264,845            
Balances at Dec. 31, 2021 160,303 $ 3 342,711 (338) (182,073)      
Balance at Beginning of period (in shares) at Dec. 31, 2021   25,269,271            
Stock-based compensation expense 2,744   2,744          
Unrealized gain on available-for-sale securities (551)     (551)        
Foreign exchange translation adjustment (7)     (7)        
Net loss (13,773)       (13,773)      
Balances at Mar. 31, 2022 148,716 $ 3 345,455 (896) (195,846)      
Balance at end of period (in shares) at Mar. 31, 2022   25,269,271            
Balances at Dec. 31, 2021 160,303 $ 3 342,711 (338) (182,073)      
Balance at Beginning of period (in shares) at Dec. 31, 2021   25,269,271            
Foreign exchange translation adjustment (198)              
Balances at Sep. 30, 2022 183,694 $ 4 411,634 (1,348) (226,596)      
Balance at end of period (in shares) at Sep. 30, 2022   37,613,829            
Balances at Mar. 31, 2022 148,716 $ 3 345,455 (896) (195,846)      
Balance at Beginning of period (in shares) at Mar. 31, 2022   25,269,271            
Exercise of stock options (in shares)   10,000            
Stock-based compensation expense 2,651   2,651          
Issuance of common stock under employee stock purchase plan (in shares)   84,558            
Issuance of common stock under employee stock purchase plan 124   124          
Unrealized gain on available-for-sale securities (292)     (292)        
Foreign exchange translation adjustment (53)     (53)        
Net loss (13,930)       (13,930)      
Balances at Jun. 30, 2022 137,216 $ 3 348,230 (1,241) (209,776)      
Balance at end of period (in shares) at Jun. 30, 2022   25,363,829            
Sale of common stock in initial public offering, net of issuance costs 60,719 $ 1 60,718          
Sale of common stock in initial public offering, net of issuance costs (in shares)   12,250,000            
Stock-based compensation expense 2,686   2,686          
Unrealized gain on available-for-sale securities 31     31        
Foreign exchange translation adjustment (138)     (138)        
Net loss (16,820)       (16,820)      
Balances at Sep. 30, 2022 $ 183,694 $ 4 $ 411,634 $ (1,348) $ (226,596)      
Balance at end of period (in shares) at Sep. 30, 2022   37,613,829